NewsBenzingaTruist Securities belässt Revolution Medicines auf „Buy“ und erhöht das Kursziel auf 240 US-Dollar Truist Securities belässt Revolution Medicines auf „Buy“ und erhöht das Kursziel auf 240 US-Dollar Benzinga 2026.10.07 17:06 (GMT+0) Open on Benzinga Other news Mizuho Maintains Outperform on Boyd Gaming, Lowers Price Target to $102 Freedom Broker Upgrades Black Hills to Buy, Raises Price Target to $78 Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700 Anthropic Introduces Claude Haiku 5.5: The Cheapest, Fastest, And Most Capable Small Model We’ve Ever Released Mizuho Maintains Outperform on IQVIA Holdings, Raises Price Target to $300 Mizuho Maintains Outperform on Willis Towers Watson, Lowers Price Target to $349
Anthropic Introduces Claude Haiku 5.5: The Cheapest, Fastest, And Most Capable Small Model We’ve Ever Released
